Cerulean Announces First Patient Dosed in Phase 1b/2 Trial of CRLX101 in Combination with Chemotherapy and Radiation in Neoadjuvant Rectal Cancer /PRNewswire/ -- Cerulean Pharma Inc ., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2 trial designed to identify the ... (more)
http://ift.tt/OsGWZQ
http://ift.tt/OsGWZQ
No comments:
Post a Comment